diabetic neuropathy

AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy

AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy

Yahoo

Sangamo Nerve Regrowth Drug Fails Key Test

Sangamo Nerve Regrowth Drug Fails Key Test

TheStreet.com

Sangamo's Phase II Results To Be Announced Monday - Expect Good News

Sangamo's Phase II Results To Be Announced Monday - Expect Good News

Seeking Alpha

Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Trial of SB-509 in Diabetic Neuropathy

Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Trial of SB-509 in Diabetic Neuropathy

Yahoo/PR NewsWire

The Wisdom Of The Crowds And Sangamo's Phase II B Clinical Trial Results

The Wisdom Of The Crowds And Sangamo's Phase II B Clinical Trial Results

Seeking Alpha

Sangamo BioSciences to raise $51M in stock offering Read more: Sangamo BioSciences to raise $51M in stock offering | San Francisco Business Times

Sangamo BioSciences to raise $51M in stock offering Read more: Sangamo BioSciences to raise $51M in stock offering | San Francisco Business Times

bizjournals.com

Submitted by moderatora on Mon, 02/07/2011 - 13:43

Device News

NeuroMetrix Hit by Lower Sales

Yahoo/Zacks

Submitted by moderatora on Wed, 01/05/2011 - 17:53

Device News

NeuroMetrix disbands direct sales, lays off 27 percent of workers

Mass Device